



Prof. Dan Peer is an Associate Professor that leads an NIH-funded lab in the Faculty of Life Science and the Faculty of Engineering at Tel Aviv University (TAU). He is also the Director of the Focal Technology Area (FTA) on Nanomedicines for Personalized Theranostics, a National Nanotechnology Initiative and the Director of the Leona M. and Harry B. Helmsley Nanotechnology Research Fund. Prof. Peer did all his training at Tel Aviv University (B.Sc., M.Sc. and Ph.D.) with two internships during his Ph.D. studies one with Cesar Milstein (Nobel Laureate, Cambridge University, UK) and one with Robert Langer at MIT (Cambridge, MA, USA), then moved to Harvard Medical School (Boston, MA, USA) for a postdoctoral training.

He was recruited back to Tel Aviv University from Harvard University in 2008 to establish the Laboratory of NanoMedicine.

Prof. Dan Peer's work was among the first to demonstrate systemic delivery of RNA molecules (new class of drugs) using targeted nanocarriers to the immune system and he pioneered the use of RNA interference (RNAi) for in vivo validation of new drug targets within the immune system.

He generated an international recognition and collaboration in inflammatory bowel diseases (IBD) and oncology area (in blood cancers, brain and ovarian cancers). He received numerous awards; among them he was recognized by the American Association for the Advancement of Science (AAAS) excellence in Science program for young investigators and was recently awarded the innovator (2010) and the breakthrough (2011, 2013) awards from the Kenneth Rainin Foundation on his pioneering work in inflammatory bowel diseases (IBD). Recently, he was awarded the 1st Untold News Award together with Prof. Rimona Margalit also from Tel Aviv University on the "Cancer Bullet" invention that might change the world.

He is an editor of several books in the field of nanomedicine, Editor of Molecular and Cellular Therapies (Springer); Editor of Biology and Medicine in Nanotechnology (IOP), an Associate Editor of the Journal of Controlled Release (Elsevier); Journal of Biomedical Nanotechnology, and of Biochemistry, and on the Editorial Boards of the Biomedical Microdevices (Springer), Cancer Letters (Elsevier), Nanomedicine: Nanotechnology, Biology and Medicine (Elsevier) and Bioconjugate Chemistry (ACS).

Prof. Peer has more than 45 pending and granted patents. Some of them have been licensed to several pharmaceutical companies and one is under a phase II clinical evaluation. In addition, based on his work, 3 spin-off companies were generated Leuko Biosciences, Quiet Therapeutics and ESPL Pharma, aiming to bring nanomedicine into clinical practice.

Dr. Peer is the President of the *Israeli Chapter of the Controlled Release Society*, and a Member of the *Israel Young Academy of Sciences and Humanities*.